Glass Jacobson Investment Advisors llc Purchases Shares of 4,782 Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 6th, 2023

Glass Jacobson Investment Advisors llc acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,782 shares of the company’s stock, valued at approximately $845,000.

Other hedge funds have also modified their holdings of the company. Lincoln Capital Corp grew its stake in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC boosted its position in shares of Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after acquiring an additional 6,154 shares in the last quarter. RFG Advisory LLC raised its position in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after acquiring an additional 594 shares in the last quarter. Willis Investment Counsel lifted its stake in Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after purchasing an additional 1,358 shares during the last quarter. Finally, Wambolt & Associates LLC boosted its holdings in Johnson & Johnson by 2.5% in the fourth quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock valued at $2,566,000 after purchasing an additional 355 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $162.68 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.77. The company has a market cap of $422.76 billion, a PE ratio of 34.03, a P/E/G ratio of 2.78 and a beta of 0.53. The stock has a fifty day moving average price of $158.33 and a 200 day moving average price of $166.96. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned $2.67 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is 94.56%.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Atlantic Securities cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday. Raymond James decreased their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. UBS Group began coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.